The FLOW trial demonstrated that semaglutide significantly improves kidney and cardiovascular outcomes in people with chronic kidney disease and type 2 diabetes, irrespective of SGLT2 inhibitor use.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2024 Diabetes Prevention Awareness Center.